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rom a Foggy Sight to
Clear Vision*
iulio Guagliumi, MD,† Marco Costa, MD, PHD‡
ergamo, Italy; and Cleveland, Ohio
Claude Monet stated that he wanted as new as possible
a view of the world.
(“Monet, The Impressionist Eye”
Musée Marmottan, Paris-16E, February 2009) (1)
he ability to image the endovascular environment of
uman coronary arteries at a micron-scale resolution is
ascinating. Optical coherence tomography (OCT) might
ulfill our need for a “corrective lens” to see the intravascular
orld the way modern therapies demand (2). Compared
ith angioscopy, its color-coded intravascular light precur-
or limited by forward view, OCT provides complete
isualization of the stent luminal surface in multiple cross-
ections (Fig. 1), allowing accurate measurements at each
trut level (3) and similar ability to detect intraluminal
See page 459
hrombus (4,5). Furthermore, OCT can differentiate be-
ween red and white large thrombus with high sensitivity
nd specificity by measuring attenuation of light within the
issue (6). However, discrimination between fibrin clot and
small amount of neointimal hyperplasia in arteries with
tent struts accompanied by their characteristic blooming
ight be more challenging (7). We have learned from
ostmortem pathology studies that patients receiving drug-
luting stents (DES) might be at increased risk of late stent
hrombosis (8). Although no cause-effect can be derived
rom such studies, these observations also suggested that
hese patients have a higher incidence of uncovered struts
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-
ions or the American College of Cardiology.
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ightlab, Medtronic, and OrbusNeich.nd fibrin deposition, raising concerns about delayed heal-
ng after DES as a mechanism of thrombosis.
In this issue of JACC: Cardiovascular Interventions, Otake
t al. (9) extended these observations by using OCT to
emonstrate a link between asymmetric stent expansion,
ercentage of uncovered stent struts 6 months after the
mplantation of sirolimus-eluting stent (SES), and local
hrombus deposition. Importantly, the present study also
upports the notion that vascular response to DES cannot
e fully appreciated by measuring neointimal hyperplasia at
cross-sectional level, as has long been performed in
ntravascular ultrasound methodology. Healing heterogene-
ty is common after DES and can vary between different
egments as well as between struts in the same cross-section
f the arterial wall. The current observation that eccentric
tent expansion is a risk factor for local thrombus formation
akes sense, because asymmetry might lead to uneven strut
pacing with higher drug concentrations being delivered
here struts are clustered, potentially delaying healing in
hose areas (10,11). Because stent asymmetry is an ex-
remely common finding and drug retention at tissue level is
ependent on specific properties (hydrophilic vs. hydropho-
ic) of each drug and tissue (12), it is difficult to speculate on
he clinical impact of slight stent asymmetry. A more careful
ook at the data will reveal that the authors appropriately did
ot claim that thrombus formed at sites of strut asymmetry
r uncovered struts, because such statements would require
ore detailed analysis and a much larger sample size. Their
ata simply suggest that such patients were more likely to
ave thrombus somewhere in the stented segment. As
xpected, their additional findings confirmed the relation-
hip between stent length and the risk of delayed healing.
iven the common heterogeneity in plaque composition
nd distribution that characterizes longer lesions, longer
ES might be more often suboptimally deployed, incom-
letely apposed and covered. Suboptimal technique is in-
eed a major predictor of both early and late thrombosis
fter DES deployment (13), highlighting the importance of
echanical factors in addition to biology as a determinant of
ascular response. The fact that none of the 53 patients in
he study by Otake et al. (9) developed stent thrombosis or
dverse thrombotic coronary events despite a high percent-
ge of local thrombus deposition at OCT deserves addi-
ional comment. First, the discordance between OCT
ndings and clinical events is neither reassuring nor dis-
ouraging, given the small sample size and short duration of
he follow-up. The relationship between these OCT obser-
ations and subsequent clinical events has to be determined
n a larger number of stents/patients and with additional
ears of clinical follow-up. The seminal work of Otake et
l. (9) certainly encourages us to proceed in our search for
etter in vivo detection of different mechanisms of DES
ate thrombosis.
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468Secondly, this study calls for an accurate revision of the
CT qualitative criteria for thrombus identification, par-
icularly in the chronic phase of stent vascular healing.
sually, the accuracy of qualitative criteria (thrombus pres-
nce/absence) is subject to the application of thresholds to
istinguish between different tissue entities. For instance,
ld (organized) thrombus has a smooth surface with a
radual decrease in light attenuation. However, the appli-
ation of such criteria when differentiating between throm-
us and neointima is less obvious in stented vessels, because
t is limited to whether a sharp intensity gap exists between
mall protruding masses and neointima. In the case of a
mall amount of neointima, it is almost impossible to
isually differentiate between a small amount of thrombus
fibrin deposit) and smooth muscle cell proliferation because
f stent strut blooming. Unfortunately, our experience in
300 consecutive blind analyses of various DES platforms
evealed that many cases might fall under this uncertain
cenario, particularly when the core lab analyst is truly blind
o the clinical status of the patient and stent assignments.
hese uncertainties between distinct entities might also
xplain the relatively high rate of local thrombus detection
ithout adverse clinical events, especially considering that
ES were likely deployed with optimal technique with a low
Figure 1. Coronary Angioscopy and Optical Coherence Tomography at Corr
After Implant
(A to D) Coronary angioscopy at 8 months. Details on shiny appearance of the
yellow plaque with tissue protrusion (D). Due to the forward view not all imag
follow-up (E to H). All tomographic views allow complete strut-level quantitatrequency of malapposition. Whether OCT is indeed too tensitive and detects any minor transient fibrin or thrombus
eposition that might occur as the result of intravascular
anipulation rather than a permanent and progressive
iologic response also remains to be defined. Hence, our
roup has taken a more conservative approach in dealing
ith intraluminal “thrombus-like” OCT images and con-
idered it under a more general description of “abnormal
ntraluminal tissue” (AIT), which can be distributed in
ifferent categories on the basis of their relationship with
overed versus uncovered and apposed versus malapposed
truts. The AIT can be further categorized on the basis of
he severely occlusive (restenosis) or nonocclusive nature of
nderlying intimal hyperplasia, because its mechanisms
ight vary (14). It is likely that these definitions will change
n the future as a larger volume of patients with long-term
ollow-up becomes available, which will hopefully provide
obust clinical end points to allow distinction between
malignant” AIT or thrombus and benign “AIT.” Further-
ore, semi-automated tissue classification algorithms will
oon become available, which should decrease our current
ubjectivity regarding thrombus assessment.
Caution must be used in extrapolating the real frequency
f subclinical thrombus formation in DES from the data of
take et al. (9), considering the small number of stents and
ding Cross Sections of a Sirolimus-Eluting Stent at Different Time Points
t struts with remaining thrombus (A,B), thin coverage (C), and underlying
w a complete lumen visualization. Optical coherence tomography at 5-year
alysis.espon
sten
es allohe fact that approximately 20% of the patients were
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469xcluded from the analysis due to incomplete image acqui-
ition. These concerns are part of the scientific debate and
hould not distract us from recognizing an important
essage from the work of Otake et al. (9), because it
einforces the need for significant improvements in stent
eometry of DES platforms to have a more predictable
echanical and biological response in complex coronary
esions. One might expect—although not specifically ad-
ressed in this article—that different DES design might
ave different strut distribution and possibly tissue responses
n various coronary geometries, as already suggested by
easuring the angle between stent struts in a phantom
odel (15). Could OCT help to optimize stent technology?
ne might foresee that OCT could contribute at various
tages of DES assessment, optimizing stent design evalua-
ion and stent deployment techniques, quantifying the
egree of stent coverage, and evaluating the mechanisms of
elayed healing and thrombus formation at the strut level
16). Ultimately, the optimal use of a novel technology
equires understanding not only of its potential but also of
ts limitations. Current OCT systems use occlusion of the
oronary artery by a balloon catheter and distal selective
oronary flushing for imaging. Alternatively, a non-
cclusive technique might be used with a high flush rate
nly in relatively short segments, to avoid intracoronary
uid overload (17). Second-generation frequency domain
CT systems have been developed and will potentially
vercome many of these practical limitations (2), allowing
s to image a long (6-cm) stented coronary segment in a
atter of a few (5) seconds with a very small amount of
ontrast and perhaps superior image quality, without re-
uirement of balloon occlusion. However, changing practice
aradigms is not an easy task and will require much more
han beautiful eye-catching images. From the age of 72
ears, Monet had begun to suffer the effects of a cataract,
hich darkened his vision, a tragedy for this painter who
oved light. For more than 10 years Monet refused to have
he operation, fearing that it might alter his perception. He
nally agreed to the operation, which proved successful and
uddenly gave him a clarity of vision he had never experi-
nced before. Optical coherence tomography was first tested
n the retina (18) and could have helped an early and
ccurate diagnosis of Monet’s sight problems, if available at
hat time. Nowadays advanced OCT is ready for primary
linical use. Through its use, we will need to learn again
ow the endovascular environment looks, a challenge even
or Monet in his own words: “The first look at the subject,” he
tressed, “was always the truest, the most faithful ” (1).
eanwhile, interventional cardiologists will continue to
xplore the capabilities and limitations of OCT technology
nd help make the medical community appreciate that it is tossible to see and understand what we have been doing to
he vessel walls of our patients.
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